Tackling the Global Diabetes Epidemic with Innovative Benchtop Analysis

Around 30 million people in the U.S. now have diabetes, and that number is on the rise. In order to better manage the condition for patients in the future, it will be essential to address the currently unmet clinical need for highly accurate and rapid diagnostic technology. Gillian Parker, senior director of global marketing, Abbott, discusses how its new benchtop analyzer, Afinion 2, will meet the growing challenges of the global diabetes epidemic.